Mylan Receives Approval for Generic Boniva

Mylan announced that the FDA has approved Ibandronate Sodium 150mg tablets, the generic version of Roche's Boniva. Ibandronate Sodium is a once monthly tablet indicated for the treatment and prevention of osteoporosis in postmenopausal women. Boniva was approved by the FDA in 2003.

Ibandronate Sodium, a bisphosphonate, is a specific inhibitor of osteoclast-mediated bone resorption. It acts as a chelator of calcium and has a high binding affinity for mineralized bone, which helps boost bone mass and reduce the risk for spinal fracture.

For more information call (800) RX-MYLAN or visit www.mylan.com.